Zusammenfassung
Die Beziehung zwischen Vorhofflimmern und Diabetes mellitus Typ 2 ist kontrovers. Die bislang publizierten Studien haben uneinheitliche Ergebnisse erbracht. Die in den letzten Jahren durchgeführten prospektiven Studien mit großen Patientenzahlen zeigen mehrheitlich eine positive Korrelation zwischen Stoffwechsel- und Rhythmusstörung. Nach multivarianter Adjustierung steigerte ein Diabetes das Risiko für Vorhofflimmern mindestens um den Faktor 2. Diese Kombination ging mit einem deutlich erhöhten Risiko für einen vorzeitigen Tod und sog. kardiovaskuläre Ereignisse (Schlaganfall und Herzinsuffizienz) einher. Es ist wahrscheinlich, dass diese Patienten ganz besonders von einer konsequenten Kontrolle des Diabetes sowie einer gerinnungshemmenden Therapie mit Antikoagulanzien und einer konsequenten Blutdruckkontrolle profitieren.
Abstract
The relationship between atrial fibrillation and diabetes mellitus type 2 is controversial, and various studies have demonstrated conflicting results. However, the majority of larger prospective studies published during recent years demonstrated a positive correlation. After multivariate adjustment diabetes increased the risk for atrial fibrillation at least two fold. This combination is associated with substantially increased risks of death and cardiovascular events (stroke and heart failure). Atrial fibrillation in patients with diabetes mellitus type 2 identifies individuals who are likely to obtain greater benefits from glycemic control and anticoagulants as well as antihypertensive therapy.
Literatur
Furberg CD, Psaty BM, Manolio TA et al (1994) Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 74:236–241
Friberg J, Scharling H, Gadsboll N, Jensen GB (2003) Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). Am J Cardiol 92:1419–1423
Go AS, Hylek EM, Philips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:2370–2375
Lavie CJ, Milani RV, Ventura HO (2009) Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 53:1925–1932
Rosengren A, Hauptman PJ, Lappas G et al (2009) Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men. Eur Heart J 30:1113–1120
Parvez B, Darbar D (2011) The „missing“ link in atrial fibrillation heritability. J Electrocardiol 44:641–644
Wanahita N, Messerli FH, Bangalore S et al (2008) Atrial fibrillation and obesity: results of a metaanalysis. Am Heart J 155:310–315
Tsang TS, Barnes ME, Miyasaka Y et al (2008) Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J 29:2227–2233
Tanner RM, Baber U, Carson AP et al (2011) Association of the metabolic syndrome with atrial fibrillation among United States adults (from the Reasons for Geographic and Racial Differences in Stroke [REGARDS] Study). Am J Cardiol 108:227–232
Watanabe H, Tanabe N, Watanabe T et al (2008) Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 117:1255–1260
Östren CJ, Merlo J, Rastam L, Lindblad U (2004) Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 6:367–374
Dublin S, Glazer NL, Smith NL et al (2010) Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med 25:853–858
Benjamin EJ, Levy D, Vaziri SM et al (1994) Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271:840–844
Aksnes TA, Schmieder RE, Kjeldsen SE et al (2008) Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol 101:634–638
Du X, Ninomiya T, Galan de B et al (2009) Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 30:1128–1135
Einhaltung ethischer Richtlinien
Interessenkonflikt. T. Meinertz und K. Sydow geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Meinertz, T., Sydow, K. Diabetes mellitus – Risikofaktor für Vorhofflimmern. Herz 39, 320–324 (2014). https://doi.org/10.1007/s00059-014-4085-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00059-014-4085-2